UNSPSC 51372007: Etorphine

This classification denotes an opioid receptor agonist with the molecular formula C25H33NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42M2Y6NU9O, chemically known as 6,7,8,14-tetrahydro-7alpha-(1-hydroxy-1-methylbutyl)-6,14-endo-ethenooripavine but generally known as etorphine, which bears US NIH Compound Identifier 26721. European Medicines Agency schedules Etorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07339MIG.

UNSPSC 51372007 Etorphine is a Commodity code covering pharmaceutical products and related delivery systems procured by state and local health agencies. Recent state and local solicitations under this code show purchasing of opioid antagonists (naloxone), drug deactivation systems, and generic multi-source pharmaceuticals through established wholesale distribution channels and direct-to-manufacturer prescription programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances administering shared contracts across multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating states). The work ranges from single-county annual procurements of specific quantities to regional and multistate framework agreements establishing manufacturer relationships and pricing models for generic pharmaceuticals and OTC products distributed through authorized drug wholesalers.

Geographic activity centers on Florida, Texas, and Minnesota, with the multistate cooperative reaching additional jurisdictions across the Pacific Northwest and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries, due July 26, 2023, on a fixed-fee basis with a two-year initial term and one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program offering direct contracting outside traditional PBM and wholesaler channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026, and contract effectiveness July 1, 2026; the RFP weights price competitiveness at 75 percent and requires cGMP and Drug Supply Chain Security Act compliance.